Phaseline

Targets › Tubulin

Tubulin: drug programs, companies and trials

72 programs from 54 companies in 478 trials: 247 Phase 2, 120 Phase 1, 80 Phase 3, 31 Phase 4; Oncology, Genitourinary, Other; next expected readout Nov 2026.

Open in Phaseline: the race on Tubulin, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
M.D. Anderson Cancer Center[18F]-4FN
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274Phase 4Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm …Dec 2026
AstellasEnfortumab Vedotin
Nectin-4 binding agent; Tubulin inhibitor
NECTIN4, TubulinPhase 4Metastatic Urothelial Carcinoma; Urothelial Cancer; Locally Advanced or Metastatic Malignant Solid Tumors; Muscle-invasive Bladder Cancer …Dec 2026
UrotronicOptilume Urethral DCB
Paclitaxel-coated balloon catheter
TubulinPhase 4Urethral StrictureJun 2027
TakedaBrentuximab Vedotin
Tubulin inhibitor; Tumor necrosis factor receptor superfamily member 8 binding agent
Tubulin, TNFRSF8Phase 4Hodgkin Lymphoma; Lymphoma; Hodgkin Disease; Ann Arbor Stage III Hodgkin Lymphoma …Dec 2027
PfizerTisotumab Vedotin
Tubulin inhibitor; Coagulation factor III binding agent
Tubulin, F3Phase 4Cervical CancerDec 2028
Vastra Gotaland RegionOptilume
Paclitaxel-coated dilatation balloon
TubulinPhase 4Urethral StrictureFeb 2029
AbbVieMirvetuximab Soravtansine
Folate receptor alpha binding agent; Tubulin inhibitor
FOLR1, TubulinPhase 3Ovarian Cancer; High Grade Ovarian Cancer; Recurrent Ovarian Cancer; Advanced High-Grade Epithelial Ovarian Cancer …Nov 2026
Sichuan Kelun-Biotech BiopharmaceuticalTrastuzumab Botidotin (A166)
Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 3HER2-positive Breast Cancer; Her 2 Positive Breast CancerNov 2026
RemeGenDisitamab Vedotin
Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin disrupting agent
ERBB2, TubulinPhase 3Urothelial Carcinoma; Breast Cancer; Gastric Carcinoma; Gastric Cancer …Dec 2026
National Cancer Institute (NCI)Vinblastine
Tubulin inhibitor
TubulinPhase 3Recurrent Low Grade AstrocytomaDec 2026
GSKBelantamab mafodotin
Tumor necrosis factor receptor superfamily member 17 binding agent; Tubulin inhibitor
TNFRSF17, TubulinPhase 3Multiple Myeloma; Amyloidosis; Plasma Cell Myeloma; Myeloma Multiple …Dec 2026
Sun Yat-sen UniversityTPF induction chemotherapy
Combination chemotherapy: polymeric micellar paclitaxel (taxane microtubule inhibitor), ci
Tubulin, TP53Phase 3Nasopharyngeal CarcinomaDec 2026
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaVinblastine
Tubulin inhibitor
TubulinPhase 3Hodgkin Lymphoma, AdultDec 2026
RochePolatuzumab vedotin
B-cell antigen receptor complex-associated protein beta chain binding agent; Tubulin inhibitor
CD79B, TubulinPhase 3Non-Hodgkin Lymphoma; Large B-Cell Lymphoma; B-cell Non-Hodgkin Lymphoma; Non-Hodgkins Lymphoma …Feb 2027
Zero Point Five TherapeuticsZP5-9676
Broad-spectrum benzimidazole anthelmintic
TubulinPhase 3Soil-Transmitted Helminthiasis (STH)Mar 2027
RocheTrastuzumab Emtansine
Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 3Breast Cancer; Ovarian Cancer; Metastatic Solid Tumor; Early Breast Cancer …Mar 2027
Merck & Co. (MSD)EV (Enfortumab Vedotin)
Nectin-4 binding agent; Tubulin inhibitor
NECTIN4, TubulinPhase 3Urinary Bladder Cancer, Muscle-invasive; Bladder Cancer; Metastatic Urothelial CarcinomaMay 2027
National Cancer Institute (NCI)Eribulin Mesylate
Tubulin inhibitor
TubulinPhase 3Metastatic Bladder Urothelial Carcinoma; Locally Advanced Bladder Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Advanced Urothelial CarcinomaMay 2027
Sun Yat-sen UniversityUtidelone
Microtubule-stabilizing agent; taxane-class chemotherapy
TubulinPhase 3Breast NeoplasmsJun 2027
Sichuan Kelun-Biotech BiopharmaceuticalEribulin (SKB264)
Tubulin inhibitor
TubulinPhase 3Triple Negative Breast CancerJun 2027
First Affiliated Hospital, Sun Yat-Sen UniversityInduction Chemotherapy (TPF regimen)
Docetaxel, cisplatin, and 5-fluorouracil combination
Tubulin, TP53, TYMS, RRM1Phase 3Locally Advanced Nasopharyngeal CarcinomaAug 2027
GIE MedicalGIE Medical ProTractX3 TTS DCB
Paclitaxel-coated balloon catheter
TubulinPhase 3Bowel; Stricture; Esophageal StrictureDec 2027
National Institute of Cardiovascular Diseases, Pakistanpaclitaxel-coated drug coated balloon (Prevail DCB, Medtronic Inc.)
paclitaxel-coated balloon catheter; paclitaxel is a microtubule stabilizer that inhibits c
TubulinPhase 3STEMI (ST Elevation MI)Dec 2027
AbbVieTelisotuzumab Vedotin (ABBV-399)
Tubulin inhibitor; Hepatocyte growth factor receptor binding agent
Tubulin, METPhase 3Non Small Cell Lung Cancer; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Solid Tumors Cancer …Feb 2028
Fidia FarmaceuticiONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Paclitaxel (microtubule stabilizer) formulated with hyaluronic acid for intravesical deliv
TubulinPhase 3Bladder Carcinoma in Situ (CIS)May 2028
UNICANCERCabazitaxel
Tubulin inhibitor
TubulinPhase 3Adenocarcinoma of ProstateJul 2041
European Organisation for Research and Treatment of Cancer - EORTCABVD regimen
Combination of doxorubicin, bleomycin, vinblastine, and dacarbazine - multi-modal chemothe
Tubulin, TOP2A, MYCPhase 3Lymphoma–
European Organisation for Research and Treatment of Cancer - EORTCBEACOPP regimen
Combination of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbaz
TOP2A, TubulinPhase 3Lymphoma–
European Organisation for Research and Treatment of Cancer - EORTCVinblastine
Tubulin inhibitor
TubulinPhase 3Lymphoma–
European Organisation for Research and Treatment of Cancer - EORTCvincristine sulfate
Tubulin inhibitor
TubulinPhase 3Lymphoma–
Memorial Sloan Kettering Cancer CenterPlinabulin
Tubulin inhibitor
TubulinPhase 2Multiple MyelomaNov 2026
AmbrxAnvatabart Opadotin (ARX788)
Tubulin inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent
Tubulin, ERBB2Phase 2HER2 Positive Metastatic Breast Cancer; Breast Neoplasms; HER2-positive, Metastatic Breast Cancer; HER2-positive Breast Cancer …Dec 2026
Shanghai Jiao Tong University School of MedicineCabazitaxel
Tubulin inhibitor
TubulinPhase 2Prostate Cancer PatientsDec 2026
Fudan UniversityAlbumin-paclitaxel
Microtubule stabilizer, promotes tubulin polymerization
TubulinPhase 2Paget Disease, ExtramammaryDec 2026
Institut du Cancer de Montpellier - Val d'AurelleGembrax
Gemcitabine and albumin-bound paclitaxel combination
TubulinPhase 2Metastatic Pancreatic CancerDec 2026
Henan Cancer HospitalUtidelone
Microtubule-stabilizing agent; tubulin polymerization inhibitor
TubulinPhase 2HER-2 Negative Breast Cancer; Metastatic Breast CancerDec 2026
Min Yan, MDUtidelone Capsule
Microtubule destabilizer; tubulin-binding agent
TubulinPhase 2Breast Cancer RecurrentDec 2026
M.D. Anderson Cancer CenterIxabepilone
Tubulin inhibitor
TubulinPhase 2Bilateral Breast CarcinomaDec 2026
Peking Union Medical College HospitalPlinabulin
Tubulin inhibitor
TubulinPhase 2Non Small Cell Lung Cancer MetastaticDec 2026
Beijing Biostar PharmaceuticalsUtidelone Capsule (UTD2)
Microtubule stabilizer; tubulin inhibitor
TubulinPhase 2Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid TumorDec 2026
National Cancer Institute (NCI)Anetumab Ravtansine
Mesothelin binding agent; Tubulin inhibitor
MSLN, TubulinPhase 2Fallopian Tube Endometrioid Adenocarcinoma; Pancreatic Adenocarcinoma; Pleural Malignant MesotheliomaJan 2027
National Cancer Institute (NCI)Ixabepilone
Tubulin inhibitor
TubulinPhase 2Endometrial Adenocarcinoma; Adult Solid NeoplasmMar 2027
Asan Medical CenterLiporaxel
Microtubule stabilizer (paclitaxel formulation)
TubulinPhase 2Gastrointestinal Stromal TumorsMar 2027
Pfizertisotumab vedotin
Tubulin inhibitor; Coagulation factor III binding agent
Tubulin, F3Phase 2Colorectal NeoplasmsMar 2027
Erasmus Medical CenterCabazitaxel
Tubulin inhibitor
TubulinPhase 2Metastatic Castration-resistant Prostate CancerMay 2027
CriteriumEribulin
Tubulin inhibitor
TubulinPhase 2Breast CancerJun 2027
RocheTrastuzumab Emtansine
Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 2Neoplasm MetastasisJun 2027
M.D. Anderson Cancer CenterCabazitaxel
Tubulin inhibitor
TubulinPhase 2Aggressive Variant Prostate Carcinoma; Castration Levels of TestosteroneDec 2027
Case Comprehensive Cancer CenterCabazitaxel
Tubulin inhibitor
TubulinPhase 2Metastatic Prostate CancerFeb 2028
ECOG-ACRIN Cancer Research GroupCabazitaxel
Tubulin inhibitor
TubulinPhase 2Castration Levels of TestosteroneApr 2028
Andrew J. Armstrong, MDCabazitaxel
Tubulin inhibitor
TubulinPhase 2Metastatic Prostate Neuroendocrine CarcinomaAug 2028
The First Affiliated Hospital of Soochow UniversityVindesine
Vinca alkaloid; microtubule inhibitor
TubulinPhase 2Adult T-cell Leukemia/LymphomaSep 2028
St. Jude Children's Research HospitalVinblastine
Tubulin inhibitor
TubulinPhase 2Hodgkin LymphomaOct 2028
St. Jude Children's Research HospitalVincristine Sulfate
Tubulin inhibitor
TubulinPhase 2Brain and Central Nervous System TumorsApr 2029
New York Medical CollegeVinblastine
Tubulin inhibitor
TubulinPhase 2Anaplastic Large Cell Lymphoma, ALK-PositiveJul 2029
St. Petersburg State Pavlov Medical UniversityVinblastine
Tubulin inhibitor
TubulinPhase 2Hodgkin LymphomaOct 2029
Shanton Pharma Pte.Colchicine (SAP-001)
Tubulin inhibitor
TubulinPhase 2Gout; Colchicine; Persistent Atrial Fibrillation; Coronary Artery Disease …–
Xiaorong DongPlinabulin
Tubulin inhibitor
TubulinPhase 2Small Cell Lung Cancer Extensive Stage–
North American Consortium for HistiocytosisVinblastine
Tubulin inhibitor
TubulinPhase 2Langerhans Cell Histiocytosis–
Peter MacCallum Cancer Centre, AustraliaCabazitaxel
Tubulin inhibitor
TubulinPhase 1Metastatic Castration-resistant Prostate CancerDec 2026
PanTher TherapeuticsPTM-101
paclitaxel-based absorbable drug product; microtubule stabilizer
TubulinPhase 1Pancreatic Ductal AdenocarcinomaDec 2026
OHSU Knight Cancer InstituteCabazitaxel
Tubulin inhibitor
TubulinPhase 1Castration-Resistant Prostate CarcinomaJan 2027
TakedaMirvetuximab Soravtansine (TAK-853)
Folate receptor alpha binding agent; Tubulin inhibitor
FOLR1, TubulinPhase 1Ovarian CancerMar 2027
EisaiEribulin (E7389)
Tubulin inhibitor
TubulinPhase 1Solid Tumor; Solid Neoplasms; Breast Neoplasms; Breast Cancer Stage IV …Mar 2027
Jiangsu Simcere PharmaceuticalSIM0388
Docetaxel polymeric micelle formulation (microtubule stabilizer)
TubulinPhase 1Malignant AscitesJun 2027
University of California, San DiegonL-TUBB4-001
Antisense oligonucleotide targeting TUBB4A
TubulinPhase 1Genetic DiseaseSep 2027
PharmaMatrix Holdings LtdCCI-001
Colchicine derivative; β-III tubulin binder
TubulinPhase 1Cancer: Recurrent and/or Metastatic Solid TumoursDec 2027
Guarionex J. DecastroCabazitaxel
Tubulin inhibitor
TubulinPhase 1Urothelial Carcinoma of the Urinary BladderApr 2028
ECOG-ACRIN Cancer Research GroupVincristine Sulfate
Tubulin inhibitor
TubulinPhase 1Recurrent Adult Lymphoblastic LymphomaDec 2028
St. Justine's HospitalVinblastine
Tubulin inhibitor
TubulinPhase 1Pediatric Low-grade GliomaApr 2030
RocheLadiratuzumab Vedotin
Tubulin inhibitor; Zinc transporter ZIP6 binding agent
Tubulin, SLC39A6Phase 1Metastatic Breast CancerSep 2030

Conditions

Multiple Myeloma (27) Breast Cancer (12) Hodgkin Lymphoma (10) Bladder Cancer (9) Lymphoma (9) Diffuse Large B-Cell Lymphoma (8) Urothelial Carcinoma (6) Gastric Cancer (6) Ovarian Cancer (6) Acute Myeloid Leukemia (6) Solid Tumor (5) Prostate Cancer (5)

Modalities

small molecule (36), mixed (18), antibody (9), protein or peptide (2)

Companies

Roche (4) National Cancer Institute (NCI) (4) European Organisation for Research and Treatment of Cancer - EORTC (4) M.D. Anderson Cancer Center (3) Takeda (2) Sichuan Kelun-Biotech Biopharmaceutical (2) Pfizer (2) St. Jude Children's Research Hospital (2) ECOG-ACRIN Cancer Research Group (2) Sun Yat-sen University (2) AbbVie (2) RemeGen (1) Henan Cancer Hospital (1) Fidia Farmaceutici (1) GSK (1) Beijing Biostar Pharmaceuticals (1) Min Yan, MD (1) Urotronic (1) Guarionex J. Decastro (1) Erasmus Medical Center (1)

Related targets

ERBB2 (5) F3 (2) TOP2A (2) TP53 (2) NECTIN4 (2) OPRM1 (2) FOLR1 (2) TNFRSF8 (1) TNFRSF17 (1) MYC (1) TYMS (1) RRM1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.